CORPORATE FINANCIALS ONLINE Fastest direct links to news from publicly-traded companies.

                Competitive Tech: Patent Upheld in Europe



For Immediate Release:


          CTT's Basic Ribozyme Patent Upheld in Europe
                                
RZYM Reports on Herzyme (TM), Treatment for Breast and Ovarian Cancer
                                


Fairfield,  CT  (July 13, 2000) - Competitive Technologies, Inc.
(AMEX:CTT) today  confirmed  that its licensee, Ribozyme
Pharmaceuticals, Inc. (NASDAQ: RZYM), announced that one of its
patents licensed to it by CTT has been reaffirmed in Europe after
opposition  proceedings.  Also, Ribozyme Pharmaceuticals has
reported on a recently discovered proprietary motif to generate
HerzymeT, now in pre-clinical studies for the treatment of breast
and ovarian cancer.

Competitive Technologies has exclusively licensed the ribozyme
technology to Ribozyme Pharmaceuticals.  Revenues generated from
sales of FDA approved RZYM products using CTT technologies will
produce royalties for CTT.

RZYM Maintains European Patent

RZYM has prevailed against its competition who contested one of
the ribozyme patents in Europe (European Patent No.  EP-B1
0291533).  European opposition proceedings, which had begun in
1996, resulted in maintenance of the fundamental "Cech" patent.

In 1997, the Japanese equivalent of the above European patent was
challenged  by RZYM's competitors and the Japanese Patent Office
rejected the opposition and decided to maintain the patent in its
entirety.

In addition to the foregoing European and Japanese patents, RZYM
has seven corresponding patents that have been issued in the
United States.  RZYM has built a formidable  multi-layered
intellectual property portfolio around its ribozyme technology by
filing and in licensing a large number of patents  covering
various aspects of the ribozyme technology.


RZYM Discovers New and Proprietary Ribozyme Motif to Generate
HerzymeT

Ribozyme Pharmaceuticals reported data describing the discovery
of a new and proprietary ribozyme motif that is nuclease stable
and works at low magnesium concentrations.  This new motif was
used to generate Herzyme T, RZYM's lead compound that is targeted
against  the  HER-2 gene for the treatment of breast and  ovarian
cancer. Herzyme is in pre-clinical studies at Medizyme
Pharmaceuticals, RZYM's joint venture with an affiliate of Elan
Corporation plc.

Ribozymes are the product of Dr. Thomas  Cech's Nobel Prize
winning science and are synthetically engineered to act as
"molecular scissors" cleaving target RNA in a highly specific
manner.  RZYM, located in Boulder Colorado, considers itself the
acknowledged leader in ribozyme therapeutic development.  RZYM is
partnered with Eli Lilly for development of an anti-Hepatitis  C
virus ribozyme which is in clinical trials designed to study
safety to assess the effect of the compound on HCV viral RNA
levels in chronic Hepatitis patients.  RZYM is partnered with
Chiron Corporation for the development and commercialization of
Angiozyme, an anti-angiogenic ribozyme designed to  inhibit  the
growth of new blood supplies to tumors and prevent tumor growth
and metastasis.  Angiozyme is in Phase I/II clinical trials in
cancer patients at the Cleveland Clinic.  RZYM is also partnered
with an affiliate of Elan Corporation plc for development and
commercialization of HerzymeT, an anti-HER-2 ribozyme for the
treatment of breast and other cancers, through RZYM's subsidiary
Medizyme Pharmaceuticals Ltd.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in identifying,
developing and commercializing innovative life sciences, physical
sciences and digital  technologies.  Competitive Technologies'
specialized expertise and experience make it a valuable partner
for companies and universities of all sizes.  CTT has been
responsible for closing hundreds of licensing agreements.   CTT
clients and licensees include: SONY Corporation, Matsushita
Electric Industrial, NTRU Cryptosystems, Inc., Palatin
Technologies, Inc. and Ribozyme Pharmaceuticals, Inc.
Competitive Technologies, Inc. is based in Fairfield, Connecticut
and has affiliates in Osaka, Japan and London, England.

Statements about the Company's future expectations, including
development and regulatory plans, and all other statements in
this document other than historical facts are "forward-looking
statements"  within the meaning of applicable Federal Securities
Laws and are not guarantees of future performance.  These
statements involve risks and uncertainties related to market
acceptance of and competition for the Company's licensed
technologies and other risks and uncertainties inherent in CTT's
business, including those set forth in Item 1 of the Company's
Form 10-K for the year ended July 31, 1999 and other factors that
may be described in CTT's filings with the SEC, and are subject
to change at any time. The Company's actual results could differ
materially from these forward-looking statements.  The Company
undertakes no obligation to update publicly any forward-looking
statement.


Direct inquiries to:

Johnnie D. Johnson
Strategic IR
800 Third Avenue
Suite 3700
New York, NY  10022
Tel. (212) 754-6565
Fax (212) 754-4333
E-mail: jdjohnson@strategic-ir.com

Web site:  http://www.competitivetech.net

For information on Ribozyme Pharmaceuticals:
http://www.rpi.com


End.